{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:17:44Z","timestamp":1771503464146,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,3,9]],"date-time":"2015-03-09T00:00:00Z","timestamp":1425859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,3,9]],"date-time":"2015-03-09T00:00:00Z","timestamp":1425859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1038\/bmt.2015.12","type":"journal-article","created":{"date-parts":[[2015,3,9]],"date-time":"2015-03-09T14:34:13Z","timestamp":1425911653000},"page":"790-794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party"],"prefix":"10.1038","volume":"50","author":[{"given":"K","family":"Horstmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Boumendil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Finke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Finel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Kanfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Milone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Bacigalupo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Chalandon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J L","family":"Diez-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Ifrah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Jurado","family":"Chacon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,9]]},"reference":[{"key":"BFbmt201512_CR1","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3324\/haematol.2011.045757","volume":"97","author":"A Sureda","year":"2012","unstructured":"Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M et al. Allogeneic stem cell transplantation after reduced intensityconditioning in patients with relapsed or refractory Hodgkin'slymphoma. Results of the HDR-ALLO study\u2014a prospectiveclinical trial by the Grupo Espanol de Linfomas\/ Trasplante deMedula Osea (GEL\/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012; 97: 310\u2013317.","journal-title":"Haematologica"},{"key":"BFbmt201512_CR2","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","volume":"29","author":"RJ van Kampen","year":"2011","unstructured":"van Kampen RJ, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-Cell Non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: An analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011; 29: 1342\u20131348.","journal-title":"J Clin Oncol"},{"key":"BFbmt201512_CR3","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(14)70161-5","volume":"15","author":"B Glass","year":"2014","unstructured":"Glass B, Hasenkamp J, Wulf G, Dreger P, Pfreundschuh M, Gramatzki M et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol 2014; 15: 757\u2013766.","journal-title":"Lancet Oncol"},{"key":"BFbmt201512_CR4","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","volume":"113","author":"CS Tam","year":"2009","unstructured":"Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C et al. Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009; 113: 4144\u20134452.","journal-title":"Blood"},{"key":"BFbmt201512_CR5","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1200\/JCO.2009.26.9100","volume":"28","author":"KJ Thomson","year":"2010","unstructured":"Thomson KJ, Morris EC, Milligan D, Parker AN, Hunter AE, Cook G et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010; 28: 3695\u20133700.","journal-title":"J Clin Oncol"},{"key":"BFbmt201512_CR6","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2011.240","volume":"26","author":"A Dodero","year":"2012","unstructured":"Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2012; 26: 520\u2013526.","journal-title":"Leukemia"},{"key":"BFbmt201512_CR7","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/bmt.2013.199","volume":"49","author":"M Koenigsmann","year":"2014","unstructured":"Koenigsmann M, Casper J, Kahl C, Basara N, Sayer HG, Behre G et al. Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed\/refractory aggressive NHL: a prospective phase-II trial. Bone Marrow Transplant 2014; 49: 410\u2013415.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201512_CR8","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/sj.bmt.1704653","volume":"34","author":"A Gratwohl","year":"2004","unstructured":"Gratwohl A, Schmid O, Baldomero H, Horisberger B, Urbano-Ispizua A. . Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indication and impact of team density. A report of the EBMT activity survey. Bone Marrow Transplant 2004; 34: 855\u2013875.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201512_CR9","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/bmt.2014.55","volume":"49","author":"JR Passweg","year":"2014","unstructured":"Passweg JR, Baldomero H, Peters C, Gaspar HB, Cesaro S, Dreger P et al. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant 2014; 49: 744\u2013750.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201512_CR10","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1046\/j.1365-2141.2000.01851.x","volume":"108","author":"M Michallet","year":"2000","unstructured":"Michallet M, Tanguy ML, Socie G, Thiebaut A, Belhabri A, Milpied N et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de moelle (SFGM). Br. J. Haematol. 2000; 108: 400\u2013407.","journal-title":"Br. J. Haematol."},{"key":"BFbmt201512_CR11","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/sj.bmt.1704645","volume":"34","author":"M Eapen","year":"2004","unstructured":"Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 2004; 34: 721\u2013727.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201512_CR12","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1200\/JCO.2012.44.7961","volume":"31","author":"M Christopeit","year":"2013","unstructured":"Christopeit M, Kuss O, Finke J, Bacher U, Beelen D, Bornh\u00e4user M et al. Second allograft for hematological relapse of acute leukemia after first allogeneic SCT from related and unrelated donors \u2013 the role of donor change. J Clin Oncol 2013; 31: 3259\u20133271.","journal-title":"J Clin Oncol"},{"key":"BFbmt201512_CR13","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/bmt.2012.267","volume":"48","author":"P Christopoulos","year":"2013","unstructured":"Christopoulos P, Schmoor C, Waterhouse M, Marks R, Wasch R, Bertz H et al. Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML. Bone Marrow Transplant 2013; 48: 901\u2013907.","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl. 1","key":"BFbmt201512_CR14","first-page":"S194","volume":"49","author":"R Vrhovac","year":"2014","unstructured":"Vrhovac R, Labopin M, Ciceri F, Finke J, Holler E, Tischer J et al. Second RIC allogeneic transplants as a rescue strategy for acute leukemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes. Bone Marrow Transplant 2014; 49 (Suppl. 1): S194\u2013S195.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201512_CR15","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol. Blood Marrow Transplant 2009; 15: 1628\u20131633.","journal-title":"Biol. Blood Marrow Transplant"},{"key":"BFbmt201512_CR16","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.bbmt.2011.02.009","volume":"17","author":"K Wudhikarn","year":"2011","unstructured":"Wudhikarn K, Brunstein CG, Bachanova V, Burns LJ, Cao Q, Weisdorf DJ. . Relapse of Lymphoma after Allogeneic Hematopoietic Cell Transplantation: Management Strategies and Outcome. Biol. Blood Marrow Transplant 2011; 17: 1497\u20131504.","journal-title":"Biol. Blood Marrow Transplant"},{"key":"BFbmt201512_CR17","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.bbmt.2011.03.010","volume":"17","author":"R Ram","year":"2011","unstructured":"Ram R, Gooley TA, Maloney DG, Press OW, Pagel JM, Petersdorf SH et al. Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant 2011; 17: 1537\u20131545.","journal-title":"Biol. Blood Marrow Transplant"},{"key":"BFbmt201512_CR18","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/bmt.2008.255","volume":"42","author":"BE Shaw","year":"2008","unstructured":"Shaw BE, Mufti GJ, Mackinnon S, Cavenagh JD, Pearce RM, Towlson KE et al. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant 2008; 42: 783\u2013789.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201512_CR19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1200\/JCO.2007.13.2415","volume":"26","author":"A Sureda","year":"2008","unstructured":"Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008; 26: 455\u2013462.","journal-title":"J Clin Oncol."},{"key":"BFbmt201512_CR20","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","volume":"31","author":"SM Smith","year":"2013","unstructured":"Smith SM, Burns LJ, van BK, Lerademacher J, He W, Fenske TS et al. Hematopoietic cell transplantation for systemic mature t-cell non-hodgkin lymphoma. J Clin Oncol 2013; 31: 3100\u20133109.","journal-title":"J Clin Oncol"},{"key":"BFbmt201512_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","volume":"32","author":"TS Fenske","year":"2013","unstructured":"Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol 2013; 32: 273\u2013281.","journal-title":"J Clin Oncol"},{"key":"BFbmt201512_CR22","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/annonc\/mdu097","volume":"25","author":"S Dietrich","year":"2014","unstructured":"Dietrich S, Boumendil A, Finel H, Avivi I, Volin L, Cornelissen J et al. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation: A retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2014; 25: 1053\u20131058.","journal-title":"Ann Oncol"},{"key":"BFbmt201512_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/bmt.2014.4","volume":"49","author":"I Avivi","year":"2014","unstructured":"Avivi I, Canals C, Vernant JP, Wulf G, Nagler A, Hermine O et al. Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma. Bone Marrow Transplant 2014; 49: 671\u2013678.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201512_CR24","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.bbmt.2009.01.012","volume":"15","author":"K van Besien","year":"2009","unstructured":"van Besien K, Carreras J, Bierman PJ, Logan BR, Molina A, King R et al. Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol. Blood Marrow Transplant. 2009; 15: 554\u2013563.","journal-title":"Biol. Blood Marrow Transplant."},{"key":"BFbmt201512_CR25","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/bmt.2013.83","volume":"48","author":"SP Robinson","year":"2013","unstructured":"Robinson SP, Canals C, Luang JJ, Tilly H, Crawley C, Cahn JY et al. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplant 2013; 48: 1409\u20131414.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201512_CR26","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","volume":"26","author":"S Le Gouill","year":"2008","unstructured":"Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 2008; 26: 2264\u20132271.","journal-title":"J Clin Oncol"},{"key":"BFbmt201512_CR27","first-page":"420","volume":"122","author":"SP Robinson","year":"2013","unstructured":"Robinson SP, Boumendil A, Finel H, Montoto S, Dreger P. . Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplantation. an analysis from the EBMT. Blood (ASH Annual Meeting Abstracts) 2013; 122: 420.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"BFbmt201512_CR28","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1182\/blood-2007-03-078592","volume":"110","author":"C Kahl","year":"2007","unstructured":"Kahl C, Storer BE, Sandmaier BM, Mielcarek M, Maris MB, Blume KG et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007; 110: 2744\u20132748.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt201512.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201512","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201512.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T18:12:34Z","timestamp":1648059154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt201512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,9]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["BFbmt201512"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2015.12","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,9]]},"assertion":[{"value":"1 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}